PMADS

Id:	acc1969
Group:	2sens
Protein:	ULK1
Gene Symbol:	ULK1
Protein Id:	O75385
Protein Name:	ULK1_HUMAN
PTM:	phosphorylation
Site:	Ser555
Site Sequence:	RTSGLGCRLHSAPNLSDLHVV
Disease Category:	Cancer
Disease:	Melanoma
Disease Subtype:
Disease Cellline:	SK-Mel-28
Disease Info:
Drug:	p53 upregulated regulator of p53 levels (PURPL)
Drug Info:	-
Effect:	modulate
Effect Info:	"PURPL deficiency leads to the phosphorylation of ULK1 mediated by AMPK at Ser555 and Ser317 sites, thereby over - activating autophagy and inducing autophagic cell death."
Note:	ncRNA
Score:	3.0
Pubmed(PMID):	34759263
Sentence Index:	34759263_3-4
Sentence:	"Here, we report a novel long noncoding RNA, p53 upregulated regulator of p53 levels (PURPL), functions as an oncogene to promote cell proliferation, colony formation, migration, invasiveness, and inhibits cell death in melanoma cells. Mechanistic studies showed that PURPL promoted mTOR-mediated ULK1 phosphorylation at Ser757 by physical interacting with mTOR and ULK1 to constrain autophagic response to avoid cell death."

Sequence & Structure:

MEPGRGGTETVGKFEFSRKDLIGHGAFAVVFKGRHREKHDLEVAVKCINKKNLAKSQTLLGKEIKILKELKHENIVALYDFQEMANSVYLVMEYCNGGDLADYLHAMRTLSEDTIRLFLQQIAGAMRLLHSKGIIHRDLKPQNILLSNPAGRRANPNSIRVKIADFGFARYLQSNMMAATLCGSPMYMAPEVIMSQHYDGKADLWSIGTIVYQCLTGKAPFQASSPQDLRLFYEKNKTLVPTIPRETSAPLRQLLLALLQRNHKDRMDFDEFFHHPFLDASPSVRKSPPVPVPSYPSSGSGSSSSSSSTSHLASPPSLGEMQQLQKTLASPADTAGFLHSSRDSGGSKDSSCDTDDFVMVPAQFPGDLVAEAPSAKPPPDSLMCSGSSLVASAGLESHGRTPSPSPPCSSSPSPSGRAGPFSSSRCGASVPIPVPTQVQNYQRIERNLQSPTQFQTPRSSAIRRSGSTSPLGFARASPSPPAHAEHGGVLARKMSLGGGRPYTPSPQVGTIPERPGWSGTPSPQGAEMRGGRSPRPGSSAPEHSPRTSGLGCRLHSAPNLSDLHVVRPKLPKPPTDPLGAVFSPPQASPPQPSHGLQSCRNLRGSPKLPDFLQRNPLPPILGSPTKAVPSFDFPKTPSSQNLLALLARQGVVMTPPRNRTLPDLSEVGPFHGQPLGPGLRPGEDPKGPFGRSFSTSRLTDLLLKAAFGTQAPDPGSTESLQEKPMEIAPSAGFGGSLHPGARAGGTSSPSPVVFTVGSPPSGSTPPQGPRTRMFSAGPTGSASSSARHLVPGPCSEAPAPELPAPGHGCSFADPITANLEGAVTFEAPDLPEETLMEQEHTEILRGLRFTLLFVQHVLEIAALKGSASEAAGGPEYQLQESVVADQISLLSREWGFAEQLVLYLKVAELLSSGLQSAIDQIRAGKLCLSSTVKQVVRRLNELYKASVVSCQGLSLRLQRFFLDKQRLLDRIHSITAERLIFSHAVQMVQSAALDEMFQHREGCVPRYHKALLLLEGLQHMLSDQADIENVTKCKLCIERRLSALLTGICA

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets

Small molecule

Antibody

PROTAC

Other modalities

Approved Drug

Advanced Clinical

Phase 1 Clinical

Structure with Ligand

High-Quality Ligand

High-Quality Pocket

Med-Quality Pocket

Druggable Family

Approved Drug

Advanced Clinical

Phase 1 Clinical

UniProt loc high conf

GO CC high conf

UniProt loc med conf

UniProt SigP or TMHMM

GO CC med conf

Human Protein Atlas loc

Approved Drug

Advanced Clinical

Phase 1 Clinical

Literature

UniProt Ubiquitination

Database Ubiquitination

Half-life Data

Small Molecule Binder

Approved Drug

Advanced Clinical

Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

ULK1-Ser403
Cancer	Intensity
BRCA	-0.248
COAD
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC	-0.243
non_ccRCC	1.42
PDAC
UCEC	-0.929

ULK1-Ser450
Cancer	Intensity
BRCA	-1.045
COAD	0.274
HGSC	2.759
ccRCC	-0.549
GBM	0.195
HNSC	-0.082
LUAD	0.128
LUSC	-0.309
non_ccRCC	-0.531
PDAC	-0.672
UCEC	-0.167

ULK1-Ser469
Cancer	Intensity
BRCA
COAD	-0.707
HGSC	0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

ULK1-Ser477
Cancer	Intensity
BRCA	-1.294
COAD	-1.933
HGSC
ccRCC	-0.059
GBM	1.281
HNSC	0.373
LUAD	0.031
LUSC	0.615
non_ccRCC	-0.527
PDAC	0.796
UCEC	0.718

ULK1-Ser479
Cancer	Intensity
BRCA	-1.395
COAD	-2.074
HGSC	-0.111
ccRCC	-0.118
GBM	1.339
HNSC	0.375
LUAD	0.012
LUSC	0.632
non_ccRCC	-0.28
PDAC	0.825
UCEC	0.796

ULK1-Ser495
Cancer	Intensity
BRCA	0.707
COAD
HGSC
ccRCC	-0.707
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

ULK1-Ser533
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM	-0.707
HNSC	0.707
LUAD
LUSC
non_ccRCC
PDAC
UCEC

ULK1-Ser538
Cancer	Intensity
BRCA	1.052
COAD
HGSC
ccRCC
GBM	-0.504
HNSC	0.59
LUAD
LUSC
non_ccRCC
PDAC
UCEC	-1.137

ULK1-Ser544
Cancer	Intensity
BRCA
COAD	-0.334
HGSC
ccRCC
GBM	-0.79
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC	1.124

ULK1-Ser556
Cancer	Intensity
BRCA	-0.39
COAD	-0.235
HGSC
ccRCC	0.266
GBM	0.413
HNSC	-1.452
LUAD	-1.307
LUSC	-0.603
non_ccRCC	0.431
PDAC	1.287
UCEC	1.59

ULK1-Ser583
Cancer	Intensity
BRCA	0.707
COAD
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC	-0.707
non_ccRCC
PDAC
UCEC

ULK1-Ser588
Cancer	Intensity
BRCA	0.008
COAD
HGSC
ccRCC
GBM
HNSC	-0.101
LUAD	-1.009
LUSC	1.243
non_ccRCC	-1.17
PDAC
UCEC	1.029

ULK1-Ser623
Cancer	Intensity
BRCA	-0.826
COAD	-0.482
HGSC	0.566
ccRCC	-1.266
GBM	0.299
HNSC	-0.126
LUAD	1.428
LUSC	-1.148
non_ccRCC	1.59
PDAC	-0.783
UCEC	0.748

ULK1-Ser630
Cancer	Intensity
BRCA	-1.653
COAD
HGSC
ccRCC	-0.014
GBM
HNSC	-0.035
LUAD	-0.306
LUSC	0.726
non_ccRCC	1.282
PDAC
UCEC

ULK1-Ser638
Cancer	Intensity
BRCA
COAD	0.304
HGSC	1.422
ccRCC
GBM	0.129
HNSC	0.38
LUAD
LUSC
non_ccRCC	-0.053
PDAC	-1.91
UCEC	-0.273

ULK1-Ser665
Cancer	Intensity
BRCA	-1.276
COAD
HGSC
ccRCC	-0.305
GBM
HNSC	0.914
LUAD	0.666
LUSC
non_ccRCC
PDAC
UCEC

ULK1-Ser758
Cancer	Intensity
BRCA	1.145
COAD
HGSC
ccRCC
GBM	-0.172
HNSC
LUAD
LUSC	0.79
non_ccRCC	-1.372
PDAC
UCEC	-0.391

ULK1-Ser775
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC	-1.041
GBM
HNSC	0.953
LUAD	0.087
LUSC
non_ccRCC
PDAC
UCEC

ULK1-Thr468
Cancer	Intensity
BRCA
COAD	-0.769
HGSC	1.13
ccRCC
GBM
HNSC
LUAD	-0.361
LUSC
non_ccRCC
PDAC
UCEC

ULK1-Thr575
Cancer	Intensity
BRCA	-0.529
COAD
HGSC
ccRCC
GBM
HNSC	-0.624
LUAD
LUSC	1.153
non_ccRCC
PDAC
UCEC

ULK1-Thr625
Cancer	Intensity
BRCA
COAD	-0.707
HGSC	0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

ULK1-Thr660
Cancer	Intensity
BRCA
COAD	0.349
HGSC	1.832
ccRCC	-0.913
GBM
HNSC	-0.817
LUAD	-0.195
LUSC	-0.817
non_ccRCC
PDAC	0.56
UCEC

ULK1-Thr755
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC	-0.541
GBM	0.392
HNSC	1.202
LUAD
LUSC
non_ccRCC
PDAC
UCEC	-1.053

PTM-Disease Association:

source: PTMD

Residue	Position	State	Disease	Class	PMID
S	555	D	Melanoma	Phosphorylation	34759263
S	555	U	Granulomatosis with polyangiitis	Phosphorylation	37720230
S	555	U	Melanoma	Phosphorylation	34759263

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links:

CTD
DMRdb